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Abstract
Background: Continued development of in-vitro procedures for expansion and differentiation of erythroid progenitor cells
(EPC) is essential not only in hematology and stem cell research but also virology, in light of the strict erythrotropism of the
clinically important human parvovirus B19.
Methodology/Principal Findings: We cultured EPC directly from ordinary blood samples, without ex vivo stem cell
mobilization or CD34+ cell in vitro preselection. Profound increase in the absolute cell number and clustering activity were
observed during culture. The cells obtained expressed the EPC marker combination CD36, CD71 and glycophorin, but none
of the lymphocyte, monocyte or NK markers. The functionality of the generated EPC was examined by an in vitro infection
assay with human parvovirus B19, tropic for BFU-E and CFU-E cells. Following infection (i) viral DNA replication and mRNA
production were confirmed by quantitative PCR, and (ii) structural and nonstructural proteins were expressed in .50% of
the cells. As the overall cell number increased 100–200 fold, and the proportion of competent EPC (CD34+ to CD36+) rose
from ,0.5% to .50%, the in vitro culture procedure generated the EPC at an efficiency of .10 000-fold. Comparative
culturing of unselected PBMC and ex vivo-preselected CD34+ cells produced qualitatively and quantitatively similar yields of
EPC.
Conclusions/Significance: This approach yielding EPC directly from unmanipulated peripheral blood is gratifyingly robust
and will facilitate the study of myeloid infectious agents such as the B19 virus, as well as the examination of erythropoiesis
and its cellular and molecular mechanisms.
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Introduction
The basic mechanisms of stem cell proliferation and
differentiation leading to erythropoiesis are well established.
In vitro studies on this topic have been carried out with
progenitor cells obtained not only from bone marrow, but also
from foetal liver and peripheral blood [1–6]. The erythropoi-
etic growth factors affect the progenitors in all these locations
[3], and many procedures have been undertaken to reproduce
the erythroid maturation in vitro including initial selection of
the CD34+ cells [7–11], adherence depletion [1,3,12,13] and
phased culturing [6,12,14]. In vitro culture of selected CD34+
cells following G-CSF mobilization of peripheral blood stem
cells (PBSC) was recently shown to yield a homogenous
population of erythroid progenitor cells fulfilling the strict
host cell specificity and growth requirements of the erythro-
tropic parvovirus B19 [15–17]. The resulting CD36+ cells
were generated with a defined combination of growth factors
[7].
Parvovirus B19 comprising three major genotypes [18] belongs
to the Parvoviridae family, genus Erythrovirus [17] and replicates
selectively in erythroid progenitor cells at BFU-E and CFU-E
stages [13,19]. For this restriction, both in vitro investigations and
clinical studies of this virus have been greatly hampered by the
unavailability of fully permissive cell cultures. The ex vivo-derived
CD36+ cell cultures [16] could thereby be of significant academic
and practical utility via propagation of this clinically important
virus, which hitherto has been done at best in primary cultures and
semipermissive cell lines [11,13,20–29]. By using the same distinct
growth factor composition [7,16], we show that the methodology
for obtaining erythroid stem cells can be markedly simplified, as
performed without mobilization or CD34+ cell preselection,
directly from ordinary samples of peripheral blood mononuclear
cells (PBMC).
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Cell Culture
56105 freshly separated PBMC from the blood samples of staff
members or the buffy coats of healthy donors were cultured in the
presence of growth factors favouring the differentiation of
pluripotent stem cells toward the erythroid lineage [7,16]. In
parallel, an equal amount of cells was cultured without the
growth factors. On days 4 or 5 the first signs of cell clustering
were seen in the cultures exposed to the growth factors (Fig. 1A).
At this stage, the cells were split 1:5 and cultured for 5 additional
days. From the initial 56105 cells their number increased to (5–
10)6107 on day 10 (Fig. 1C); the overall increment was (1–
2)6102-fold. In phenotype, the cells with the growth factors
showed a progressive increase both in size and number, and
particularly in extent of clustering (Fig. 1A) reaching a maximum
by day 10 (Fig. 1C). In the absence of growth factors, apoptotic
bodies and cell debris abounded, until on day 10 no living cells
were seen (Figs. 1B–C).
Flow Cytometry
PBMC were analysed by flow cytometry immediately following
separation (day 0) and after 10 days of culture with the growth
factors. The cells were analysed for the main lymphocytic,
monocytic and erythroid marker expression patterns. During this
time a profound increase in erythroid cells was observed, with a
decrease in lymphocytes and monocytes (Figs. 2A–B). On day 0,
only ,0,25% of the cells were CD34+. Specifically, the day 0 cell
population comprised primarily lymphocytes and monocytes,
.50% CD3+ (CD4+ or CD8+), ,10% CD56+, and ,20%
CD14+ (Fig. 2B). All these values approached 0 on day 10. On
the other hand, the erythroid progenitor cells that were barely
detectable on day 0 increased to ,95–100% by day 10, as
indicated by CD71 and glycophorin expression patterns
(Figs. 2A–B). Importantly, on day 10, CD36 positivity reached
with some donors ,100% of the cells. On day 0 this marker
showed variable expression, in coexpression with the monocyte
marker CD14 [30]. Of note, some of our donors presented with
mononuclear CD36+ CD142 cells, as recently identified [31]. As
Figure 1. Phenotypic changes during cell culture from peripheral blood. (A) PBMC were isolated and cultured with growth factors favouring
erythroid expansion and observed with an optical inverted microscope (Olympus IX71). Photographs were taken at 106 magnification with a
Hamamatsu C8484-05G digital camera. (B) PBMC cultured as in panel A, but without the growth factors. (C) Numbers of cells cultured with or without
the growth factors. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0009496.g001
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expressing cells showed variability among the donors, with a
highest value of .20% (Fig. 2B), while on day 10 of culture
nearly every cell co-expressed this B19 virus receptor along with
CD36 (Fig. 2D).
Comparison of Erythroid Progenitor Cells Generated from
Unselected PBMC and Selected CD34+ Cells
In order to determine which cell type(s) represented the growth
factor target(s), we followed in parallel cultures from unselected
PBMC and from pure populations of preselected CD34+ cells.
The cultures were analyzed by flow cytometry on days 0 and 10.
Differentiation of the CD34+ cells into erythroid progenitors fully
comparable with those from the unselected PBMC could be
verified. Indeed, as opposed to the very low fraction of CD34+
cells in the PBMC on day 0 (Figs. 2A–B), the percentages of
glycophorin+ and CD36+ erythroid progenitors were $70% and
$80%, respectively, from the cultures of unselected PBMC and
selected CD34+ cells (Fig. 2C).
B19 Virus Permissivity of the Generated Erythroid
Progenitor Cells
The erythroid progenitor cells expanded from peripheral blood
were analysed for their functional competence by a virological
approach. As the cells harboured both globoside P antigen and
CD36 (Fig. 2D), they were considered suitable for a B19
parvovirus in vitro infection assay.
In vitro infection. Both of the procedures performed [16,32]
turned out comparable in all the downstream analyses.
Furthermore, we observed no difference in any of the B19
infection parameters between the cells obtained from B19
seropositive and seronegative donors.
Nucleic acid analyses. DNA and RNA were extracted from
the infected and uninfected cells at 2, 24 and 48 hrs, and real-time
PCR and RT-PCR were performed. The contiguous primers
annealing to the common exon of the B19 genome were used for
both DNA and RNA detection, the latter after DNase treatment.
DNA was quantified by interpolation on a standard curve
obtained with serial dilutions of plasmid DNA containing the
Figure 2. Flow cytometry analysis during culture with growth factors. Expression of cellular membrane antigen markers on day 0 and after
10 days of culture in presence of growth factors. FITC or PE labelled primary monoclonal antibodies for CD markers were used for cell staining. For
each monoclonal antibody the correspondent anti-isotype antibody was used in parallel to test the specificity of the staining. Polyclonal rabbit
antibody and antirabbit FITC were used to detect globoside P. (A) The histogram represents the percentages of positive cells to each marker
analyzed; average of 5 experiments. Bars indicate percentage error. (B) Flow cytometry patterns of main lymphocyte, monocyte and erythroid
markers on day 0 and on cultured cells. Representative experiment. Images were corrected for color uniformity by AdobePhotoshop software. (C)
Comparison between unselected PBMC and CD34
+-selected cells as culture source. Expression of CD36 and glycophorin on day 10 of culture.
Representative experiment. (D) Expression of CD36 and globoside P on day 10. Representative experiment.
doi:10.1371/journal.pone.0009496.g002
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of the DNA copy numbers was observed at 24–48 hrs post
infection (Fig. 3A). Our assessment of the total B19 mRNA signal
(Fig. 3C) took into account both the amount of DNA amplified by
PCR (Fig. 3B) in absolute numbers and the extent of background
DNA signal obtained by RT-PCR in the absence of reverse
transcriptase. In RNA detection, the spliced VP transcripts,
corresponding to the bands of 148 and 268 bp, were seen in
agarose gel electrophoresis (Fig. 3D) following amplification with
the non-contiguous primers [33].
Protein expression. The erythroid progenitor cells were
analyzed for both structural (VP2) and nonstructural (NS1)
proteins of the B19 virus, and in both native and denaturing
conditions (Fig. 4). Immunofluorescence staining was performed
on the infected and uninfected cells fixed at 2 and 48 hrs. At
48 hrs post-infection .50% of the cells were positive for VP2 and
,50% for NS1, by contrast to 0% at 2 hrs post infection (Fig. 4A).
Correspondingly, in Western blotting a strong VP2 band
(58 kDa) was obtained from the cells lysed at 48 hrs post-
infection, as opposed to none from the negative control cells
(Fig. 4B).
Extent of Increase of Erythroid Progenitor Cells
Considering the proportion of hemopoietic CD34+ stem cells
initially present in the unselected PBMC (Figs. 2A–B) and the
expansion of overall cell number during culture (Fig. 1C), we first
calculated the relative fold increase of the cells expressing the
erythroid progenitor markers (CD34 vs. CD36 and CD71 along
with glycophorin) (Fig. 5: grey bars; Table 1: rows 1, 2, 3).
Moreover, the immunofluorescence results, in which .50% of the
cells infected on day 10 expressed the B19 antigens, were taken
into account together with the aforementioned variables, to
calculate the fold increase of B19 permissive cells. As shown in
Figure 5 (white bar) and Table 1 (row 4), (i) the overall cell count
increased 100–200 fold; and concomitantly with this (ii) the
proportion of EPC multiplied from ,0.5% to .50%. I.e. it can be
concluded that, during the in vitro culture our B19 permissive
erythroid cells expanded .10 000-fold.
Discussion
For in vitro erythropoiesis many different approaches have been
taken, utilizing pluripotent stem cells from a variety of sources
Figure 3. Cellular B19 virus DNA and RNA levels during in vitro infection. DNA and RNA were extracted following B19 in vitro infection of
the obtained EPC. Real-time PCR and RT-PCR were performed. (A) B19 DNA fold increase at 24–48 hrs versus 2 hrs post-infection. Average of 3
experiments. Error bars indicate standard deviation. (B) Viral DNA pattern in cells harvested after in vitro infection. Absolute quantification was
determined following qPCR of the extracts at different time-points. Representative experiment. (C) Relative amount of B19 RNA in cells harvested
after infection. The obtained values take into account the qPCR results of the DNA template and the RNA in both presence and absence of
retrotranscriptase. Representative experiment. (D) Agarose gel analysis of real-time RT-PCR amplicons. Lane 1: molecular weight markers. Spliced RNA
in cells at 2 hrs (lane 2), 24 hrs (lane 3) and 48 hrs (lane 4) post-infection.
doi:10.1371/journal.pone.0009496.g003
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of peripheral blood of ordinary blood donors in the absence of bone
marrow stem cell mobilization or of ex vivo priming of any other
type, and selectively expanded the contained stem cells by in vitro
culture in the presence of a defined combination of growth factors
favouring erythropoietic commitment and expansion [7]. Indeed,
our approach did not include any cell preselection, neither positive,
for CD34+ [8–11], nor negative, against CD3-CD14- [13], nor
adherence depletion [1,3], and not even phased culturing [6,12,14]
except for a single passage. Our straightforward approach yielded
the desired population of erythroid progenitor cells comparable in
purity and yield to the previously introduced approach including
mobilization and preselection. Our comparison between selected
CD34+ stem cells and unselected PBMC verified qualitatively and
quantitatively similar yields of EPC. By this robust approach the
initially diverse PBMC evolved in vitro, with natural selection toward
a notablyuniformpopulationofcolony-formingcellsphenotypically
characteristic of erythroid progenitors [6,8,12,14,35]. Of the cells
cultured for 10 days nearly 100% expressed the marker combina-
tion of erythroid progenitors, CD36, CD71 and glycophorin, and
were devoid of the lymphocyte, monocyte or NK markers CD4,
CD8, CD3, CD14, CD56.
The aforementioned markers define best the immunophenotype of
erythroid progenitor cells, as shown in a large number of studies
Figure 4. Permissivity of EPC for parvovirus B19 virus infection. Viral protein expression. (A) Immunofluorescence staining for viral capsid
(VP) and nonstructural (NS1) proteins of cells infected on day 10 of culture, and fixed at 2 or 48 hrs post-infection. Monoclonal mouse antibody and
human antibody were used to detect VP1-VP2 and NS1 respectively, followed by anti-mouse or anti- human FITC antibodies. The cells were observed
with a Zeiss Axioplan 2 UV microscope. Photographs taken at 206magnification. (B) Western blotting of lysates of uninfected (lane 2) or infected
(lane 3) cells labeled with the monoclonal B19 capsid protein (VP) antibody. Infected cells labeled with isotype control antibody (lane 4). Lane 1:
molecular weight markers.
doi:10.1371/journal.pone.0009496.g004
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receptor CD71 have been identified as the reference molecules of
erythroblasts. Although a well-established marker for erythroid
progenitors [2,16], CD36 on its own is far from cell type specific,
as it occurs within the PBMC in monocytes, macrophages and even
platelets, and participates in a variety of functions [30,38]. However,
we consider it appropriate to include CD36 as an indicator of
erythropoietic commitment in concert with glycophorin and CD71
[10,16], which were almost absent at the beginning yet occurred in
nearly every cell at the end of our expansive culturing.
The expanded EPC were verified to be functionally competent by
permissivity to B19 parvovirus infection. The B19 in vitro infection
procedures employed here have been previously used in the
documentation of functionality of mobilized, preselected (CD34+) cells
[16,32]. Our EPC obtained bypassing those steps were similarly
susceptible to B19 virus infection, in terms of DNA replication (increase
of 3 logs), mRNA transcription and protein production (both NS and
capsid). Neither the presence of antiviral antibodies nor virus-specific T
cells [39] in the donor blood affected the virological outcome.
Previous studies have addressed the role of accessory cells in
establishing ideal conditions for the erythropoietic proliferation and
commitment [1,3,6,36,40,41]. In a comparative study with different
cell lineages [36], cellular diversity has turned out to be essential
compared with selected pluripotent cells. Our main finding, obtained
with the novel procedure, is in line with this. The identification of the
factors accounting for the differentiation within this condensed in vitro
population is an interesting subject of further investigation.
Our procedure for EPC generation is gratifyingly robust. This
straightforward technique can be foreseen to facilitate B19 virus
basic research both in its molecular and cellular aspects, as well as
to simplify the measurement of B19 virus neutralizing immunity
[39,42–46]. The latter studies have been hampered greatly by the




All the samples used during this study were obtained following
written informed consent from the donors. This study was
approved by the Ethical committee of the Helsinki University
Central Hospital.
Blood Samples and Cells
Peripheral blood samples were obtained into Vacutainer tubes
from nonsymptomatic staff members. Leukocyte-enriched buffy
coats of healthy blood donors were obtained from the Finnish Red
Cross Blood Transfusion Service, Helsinki, Finland. From these
preparations peripheral blood mononuclear cells (PBMC) were
isolatedbyFicoll-PaquecentrifugationandtwoPBSwashes[39,42].
Cell Culture
From the PBMC, erythroid progenitor cells (EPC) were
generated via culture in an expansion medium containing
erythropoietic growth factors [7,16]. Briefly, 56105 PBMC were
cultured in MEM (HyClone, Logan, UT) supplemented with the
serum substitute BIT 9500 (StemCell Technology, Vancouver,
BC, Canada), diluted 1:5 for a final concentration of 10 mg/ml
bovine serum albumin, 10 mg/ml rhu insulin, and 200 mg/ml
iron-saturated human transferrin, enriched with 900 ng/ml
ferrous sulfate (Sigma, St. Louis, MO, USA), 90 ng/ml ferric
nitrate (Sigma), 1 mM hydrocortisone (Sigma), 3 IU/ml rhu
erythropoietin (Janssen-Cilag, Espoo, Finland), 5 ng/ml rhu IL-3
(R&D Systems, Minneapolis, MN, USA), and 100 ng/ml rhu stem
cell factor (Peprotech, London, UK). The cells were maintained at
Figure 5. Expansion of EPC cultured from unselected PBMC. Grey bars: fold-increase of cells expressing CD36, CD71 and glycophorin markers
on day 10 of culture. The values are based on the flow cytometry analysis of Figure 2 and the cell counts of Figure 1C and Table 1. White bar: fold-
increase of B19 virus permissive EPC; percentage of cells expressing capsid proteins at 48 hrs post-infection (Fig. 4A). Bars represent error percentage.
doi:10.1371/journal.pone.0009496.g005
Table 1. Expansion of EPC directly from peripheral blood.
Erythroid markers Fraction (%) day 10
Total relative fold
increase
EPC glycophorin+ 99.42 6.78E+04
EPC CD71+ 99.22 6.77E+04
EPC CD36+ 99 6.75E+04
EPC B19+ 50 3.41E+04
Rows 1–3: Fold increase of cells expressing erythroid markers CD36, CD71 and
glycophorin on day 10 of culture; the values are based on CD34
+ fraction (%) on
day 0 (0.22%) and on the expansion factor of 150, expressed as an average fold
increase throughout the culture (Fig. 1C). The first column indicates the values
obtained during the flow cytometry analysis of the three markers (Fig. 2B).
Row 4: Fold increase of B19 virus permissive cells (row 4); the values are based
on CD34
+ fraction (%) on day 0 (0.22%) and on the expansion factor of 150,
expressed as an average fold increase throughout the culture (Fig. 1C). The first
column indicates the percentage of cells expressing capsid proteins (Fig. 4A).
EPC represents erythroid progenitor cells.
doi:10.1371/journal.pone.0009496.t001
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(Olympus IX71, Center Valley, PA, USA) for phenotypic changes.
For control, PBMC of the same donors were grown in MEM
either without the aforementioned substances or with only BIT
(BSA, insulin, transferrin).
Upon observation of the initial small clusters on day 561, the
cultures were split (1:5) into their respective media.
For comparison, from some of the blood samples, CD34+ cells
were first isolated by CD34 Microbead Kits (Miltenyi Biotech,
Bergish Gladbach, Germany) containing magnetic beads conju-
gated to CD34 antibody, and were then cultured as described.
Flow Cytometry
56105 of each cell population were analysed both before culture
(day 0) and on day 10 with FACScan (Becton Dickinson, Franklin
Lakes,NJ,USA).Thecellswerewashedthrice(inPBScontaining2%
FCS) and treated for 30 min at 4uC with FITC-labelled monoclonal
antibodies for CD34, CD45, CD71, CD1a, CD3, and with
phycoerythrin (PE)-labelled monoclonal antibodies for CD36,
CD14, CD56, and glycophorin (BD Biosciences, San Jose, CA,
USA); and with a mixture of anti-CD4-PE and anti-CD8-FITC
(DakoCytomation, Glostrup, Denmark). Anti-isotype antibodies (BD
Biosciences) were used in parallel, for specificity control. Globoside P
antigen, the B19 virus cell surface receptor [19], was examined by
polyclonal rabbit antibodies (Matreya, Pleasant Gap, PA, USA)
followed by anti-rabbit FITC (DakoCytomation). All the stained cells
were washed thrice with, and resuspended in, PBS (200 ml).
Parvovirus B19 Permissivity Study
Serology. All the PBMC donors’ sera were studied for the
presence of B19 virus IgG and IgM antibodies as described [43].
In vitro infection. Cell cultures of day 10 were infected at 103
genome equivalents per cell with B19 virus from a high-titer viremic,
B19-seronegative donor plasma [48]. Two different in vitro infection
procedures were used in parallel [16,32]. In one, 26104 cells in 10 ml
volumes on a 96-well plate were treated with 10 mlo fd i l u t e dv i r u sf o r
2 hrs at 4uC, washed and maintained at a final concentration of
26104/100 ml, at 37uC. In the other, 26106 cells in 500 mlv o l u m e s
on a 24-well plate were treated with the virus at 4uC, under agitation,
washed and maintained at a final concentration of 26105/ml, at
37uC. For control, mock-infected cultures, without addition of virus,
were maintained in parallel with the infected ones. Aliquots of the test
and control cultures were harvested at 2, 24 and 48 hrs post infection
for DNA, RNA and protein analyses.
Nucleic acid analyses. DNA and RNA were extracted from
the infected and uninfected cells at various times post infection, as
described [33,49]. Briefly, 105 cells were lysed with Proteinase K
(100 mg/ml; Fermentas Finland, Helsinki, Finland) and 1% SDS
in 100 mM NaCl, 10 mM EDTA, 10 mM Tris-Cl pH 7.5 for 1 h
at 55uC, and the nucleic acids were extracted by phenol-
chloroform followed by ethanol/Na-acetate precipitation. RNA
was selectively extracted with ToTally RNA purification kit
(Ambion, Austin, TX, USA) and treated with DNase
TurboDNAfree (Ambion). A constant amount of both extracts,
corresponding to ,104 cells per reaction, was amplified, in
parallel for viral DNA and mRNA, by the Light Cycler (Roche
Applied Sciences, Basel, Switzerland) by using Quantitect
SYBRgreen PCR and Quantitect SYBRgreen RT-PCR Kits
(Qiagen, Hilden, Germany), respectively. The contiguous primers,
corresponding to the common central exon of the viral genome
and its thermal profile have been described [33,49]. The absolute
quantity of viral DNA was determined by interpolation using a
standard curve constructed with serial dilutions (108–100 geq) of a
plasmid containing the viral coding region (GenBank AY504945).
Standards were included in each assay and linearity of the curve
was confirmed. The RT-PCR was performed in the presence
(RT+) and absence (RT-) of reverse transcriptase with the primer
pair used for DNA amplification. The actual signal due to mRNA
was obtained taking into account the Ct values [RT+] and [RT2],
and the Ct corresponding to the DNA template. The relative
increase at the various time points was then calculated. For
additional evidence of RNA specificity of detection, non-
contiguous primers (HR6) for spliced transcripts [33] were used.
Specificity of the real-time PCR and RT-PCR results was
confirmed by melting curve analysis and agarose gel
electrophoresis of the amplicons for the contiguous and the non
contiguous primer pairs, respectively. For extraction control, PCR
for beta-actin DNA was performed in parallel [50].
Protein analysis. Cell-associated B19 proteins were
visualized by immunofluorescence microscopy. At 2 hrs and
48 hrs post-infection 105 cells were spotted on glass slides
(Biomerieux, Marcy l’Etoile, France), air-dried and fixed in
methanol-acetone (1:1) for 10 minutes at 220uC. Monoclonal
mouse antibody for both VP1 and VP2 capsid proteins (clone 521-
5D; Chemicon Millipore, Billerica, MA, USA) or monoclonal
human antibody for NS1 protein [51] (a generous gift from
Susanne Modrow) were visualized by anti-mouse or anti-human
IgG-FITC (DakoCytomation), respectively. After washing and
embedding, fluorescence was observed and photographed with a
Zeiss Axioplan 2 (Carl Zeiss, Jena, Germany) UV microscope.
Western Blotting of lysates from ,36104 infected or uninfected
cells was performed as described [42] with reducing 7.5%DS-
PAGE gels, by using a monoclonal B19 virus capsid antibody
(NovoCastra Laboratories, Wetzlar, Germany) followed by anti-
mouse IgG-HRP (DakoCytomation). The corresponding isotype
control antibody (R&D Systems) was applied for specificity
control.
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